Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age

Data for patients with bone metastases (BMs) of differentiated thyroid carcinoma (DTC) were retrospectively studied to identify factors associated with survival. We especially studied the impact of therapies. Among the 1977 patients followed for DTC in our department from 1958 to 1999, 109 (77 females and 32 males; age range, 20–87 yr) presented BMs. All patients except 1 underwent total thyroidectomy, followed by radioiodine therapy (≥3.7 gigabecquerels) in 95 cases. Survival rates at 5 and 10 yr were 41% and 15%, respectively. Univariate analyses indicated that a young age at BM discovery (P < 0.005) and the discovery of BM as a revealing symptom of DTC (P < 0.05) were features significantly associated with improved survival as well as radioiodine therapy (P < 10−4) and BM complete surgery (P < 0.02). Using multivariate analysis, the detection of BMs as a revealing symptom of thyroid carcinoma (P < 0.0005), the absence of metastasis appearance in other organs than bones during the follow-up (P < 0.03), the cumulative dose of radioiodine therapy (P < 0.0001), and complete BM surgery in young patients (P < 0.04) appeared as independent prognostic features associated with an improved survival.

Download Full-text

Carotid artery rupture following radioiodine therapy for differentiated thyroid carcinoma

Arquivos Brasileiros de Endocrinologia & Metabologia ◽

10.1590/s0004-27302011000600009 ◽

2011 ◽

Vol 55 (6) ◽

pp. 419-425 ◽

Cited By ~ 2

Author(s):

Danilo da Silva Cunha ◽

Maria Izilda Previato Simões ◽

Dionísio Nepomuceno Viviani ◽

Domingos Boldrini ◽

Euclides Timóteo da Rocha ◽

...

Keyword(s):

Side Effects ◽

Carotid Artery ◽

Thyroid Carcinoma ◽

Radioiodine Therapy ◽

Subcutaneous Tissue ◽

Differentiated Thyroid Carcinoma ◽

High Avidity ◽

Serious Adverse Events ◽

Carotid Artery Rupture ◽

Base Of The Skull

INTRODUCTION: Radioiodine therapy for patients with differentiated thyroid cancer aims at reducing tumor recurrence by eradicating residual macro- and microscopic foci. Side effects are generally rare, tenuous and transient, with little clinical significance. OBJECTIVE: To report a rare case of differentiated thyroid carcinoma presenting a large expansive solid mass at the base of the skull, with invasion of the left masticatory muscle and adjacent subcutaneous tissue, and without invasion of the carotid space, which evolved to carotid artery rupture following radioiodine therapy. DISCUSSION: Side effects are uncommon after radioiodine therapy and when present, have mild intensity. Serious adverse events are very rare, especially those arising from structures not directly invaded by metastatic tissue with radioiodine uptake, as occurred in this case. This occurrence serves to raise awareness of the need for increased care when using radioiodine therapy on high-avidity masses located close to important structures.

Download Full-text

Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma

Clinical Endocrinology ◽

10.1046/j.1365-2265.2000.00998.x ◽

2000 ◽

Vol 52 (5) ◽

pp. 653-659 ◽

Cited By ~ 46

Author(s):

K. M. Van Tol ◽

J. M. Hew ◽

P. L. Jager ◽

A. Vermey ◽

R. P. F. Dullaart ◽

...

Keyword(s):

Thyroid Carcinoma ◽

Bone Metastases ◽

Radioiodine Therapy ◽

Differentiated Thyroid Carcinoma

Download Full-text

Gastrointestinal side effects of the radioiodine therapy for the patients with differentiated thyroid carcinoma two days after prescription

World Journal of Nuclear Medicine ◽

10.4103/1450-1147.174703 ◽

2016 ◽

Vol 15 (3) ◽

pp. 173 ◽

Cited By ~ 4

Author(s):

Sina Izadyar ◽

Mehran Pashnehsaz ◽

Abbas Takavar ◽

SeyedSalman Zakariaee ◽

Mahmoud Mahmoudi ◽

...

Keyword(s):

Side Effects ◽

Thyroid Carcinoma ◽

Radioiodine Therapy ◽

Differentiated Thyroid Carcinoma ◽

Gastrointestinal Side Effects

Download Full-text

131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

Nuklearmedizin ◽

10.1055/s-0038-1628878 ◽

1987 ◽

Vol 26 (03) ◽

pp. 139-142 ◽

Cited By ~ 4

Author(s):

G. Arning ◽

O. Schober ◽

H. Hundeshagen ◽

Ch. Ehrenheim

Keyword(s):

Serum Level ◽

Thyroid Carcinoma ◽

Bone Metastases ◽

Differentiated Thyroid Carcinoma ◽

Serum Thyroglobulin ◽

Thyroglobulin Level ◽

Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

Download Full-text